BioSpace News Archive

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will host a conference call on Friday, June 11, 2021, at 8:00 am ET,

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, today announced it will present primary and secondary endpoint data, including new post hoc analyses, from the pivotal Phase 3 REST-ON clinical trial at SLEEP 2021, at the 35th Annual Meeting

Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, today announced the expansion of its pipeline with the introduction of Enriched Tear Film (ETF™) Gene Therapy and proof-of-concept in vivo study results from its first gene therapy candidate, OC-101.

Krystal Biotech Inc., the leader in redosable gene therapies for rare diseases, announced participation in two upcoming virtual investor conferences.

Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today the publication of data from the REDUCE (“Reliable Endoscopic Diagnosis Utilizing Cleansing Enhancement”) study in an article titled

Rain Therapeutics Inc., a clinical-stage company developing precision oncology therapeutics, today announced a master program and a genomic analysis platform agreement for comprehensive genomic profiling tests utilizing artificial intelligence and precision medicine company Tempus’ genomic analysis platform.

Histogen Inc. announced an update on its pipeline focus following a strategic evaluation of its regenerative medicine platform technology development programs with the goal of focusing on high value orthopedic indications, creating pipeline synergies and maximizing resources in an effort to further drive long-term shareholder value.

Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Onconova has been selected to present at 2021 BIO Digital, being held virtually June 10-11 and 14-18, 2021.

Proceeds will support development of antibody drugs and discovery platform targeting pro-tumorigenic factors produced by fibroblasts in the tumor microenvironment, rendering resistant cancers treatable

Summit Therapeutics Inc. invites our shareholders and other interested parties to attend our Company’s Annual Shareholders’ Meeting, which will be held virtually on Wednesday, June 16, 2021, at 1:00 pm Eastern Time.